{
    "clinical_study": {
        "@rank": "85560", 
        "arm_group": {
            "arm_group_label": "Bevacizumab plus chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Bevacizumab:\n7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;\nOxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2\uff0cd1-d14, bid\uff0ceach 21 day cycle;\nOxaliplatin+5-Fluorouracil+ Levomisole\uff08FOLFOX\uff09:\nOxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole\uff08LV\uff09: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil\uff085-FU\uff09 :400mg/m2 iv,d1,then 1200mg/m2/d \u00d72d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
        }, 
        "brief_summary": {
            "textblock": "A multi-center, non-random, open study ,to observe efficacy and safety of  bevacizumab plus\n      Oxaliplatin based multidrug chemotherapy as conversion therapy for patients with previously\n      untreated unresectable liver metastases from colorectal cancer."
        }, 
        "brief_title": "Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Liver Metastases", 
            "Colorectal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES\uff1aTo assess the objective response rate(ORR)\uff088 weeks after chemotherapy\uff09\n\n      SECONDARY OBJECTIVES\uff1a\n\n        1. To assess the R0 resection rate of liver metastases\uff088 weeks after chemotherapy\u3001every\n           three months follow-up 1 time in R0 postoperative 1-2 years\u3001Every six months follow-up\n           1 time in R0 postoperative 2-5 years\uff09\n\n        2. To assess the incidence of adverse events of level 3-4 \uff08Bleeding\u3001Gastrointestinal\n           Perforation\u3001Anastomotic Fistula\u3001Hypertension\u3001Wound Healing Delay\uff09\uff088 weeks after\n           chemotherapy\uff09"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written inform consent form\n\n          2. histologically or cytologically confirmed Colorectal Adenocarcinoma\n\n          3. Age\u226518 and \u226480 years old\n\n          4. Primary colorectal cancer and liver metastases\uff0cLiver lesions determined to be\n             unresectable by multidisciplinary team (MDT) \uff08primary lesions surgically removed\uff09\n\n          5. Simultaneity or heterochrony metastases\n\n          6. Colorectal cancer lesions from anal edge at least 8 cm\n\n          7. Within 6 months did not receive any chemotherapy, including targeted therapy\n\n          8. One or more measurable lesions, conventional Computed Tomography(CT) scanning\n             measurement diameter at least 20 mm [Response Evaluation Criteria In Solid\n             Tumors(RECIST) standard]\n\n          9. Eastern Collaborative Oncology Group(ECOG) 0 or 1\n\n         10. Expected lifetime at least for 12 weeks\n\n         11. Screening within 7 days\uff0c the ability of bone marrow, liver and kidney function\n             reserve enough\uff1bAbsolute neutrophil count\uff08ANC\uff09\u22651.5x109/L; hemoglobin\u22659.0g/dl; platelet\n             count\u226580 x109/L; Total Bilirubin(TBil)\u22641.5 x upper level of normal range(ULN);\n             Alanine Aminotransferase(ALT) and Aspartate Aminotransferase(AST)\u22642.5 x ULN(Patients\n             with hepatic metastasis\u22645x ULN); alkaline phosphatase\u22644 x ULN; serum creatinine\u22641.5 x\n             ULN;\n\n         12. Women of reproductive age should take effective contraceptive measures;\n\n        Exclusion Criteria:\n\n          1. Arrhythmia requiring medication\uff08except \u03b2- receptor blocking pharmacon and\n             digoxigenin\uff09\uff0csymptomatic coronary artery disease and myocardial ischemia [myocardial\n             infarction (\u22646months before enrollment)]\uff0ccongestive heart failure [\u2265New York Heart\n             Association(NYHA)2];\n\n          2. History of HIV infection,Chronic hepatitis B or hepatitis C of active phase(high copy\n             virus DNA);\n\n          3. Other activated serious infection [>National Cancer Institute-Common Toxicity\n             Criteria(NCI-CTC) 3.0];\n\n          4. Any extrahepatic metastases;\n\n          5. Seizures requiring medication(such as steroids or antiepileptic therapy);\n\n          6. Other malignancies in the past 5 years (except curatively treated basal cell\n             carcinoma of the skin and/or in situ carcinoma of the cervix);\n\n          7. Chronic inflammatory bowel disease, intestinal obstruction;\n\n          8. Drug abuse and medicine, psychology or social conditions may interfere with patients\n             to participate in research or the results of the evaluation have influence;\n\n          9. Known or suspected allergy to any investigational drug in this study;\n\n         10. Any unstable condition or is likely to endanger the patient safety and compliance\n             situation;\n\n         11. Pregnant or lactating women not using or refusing to use effective non hormonal means\n             of contraception;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763450", 
            "org_study_id": "Avastin Study"
        }, 
        "intervention": {
            "arm_group_label": "Bevacizumab plus chemotherapy", 
            "description": "Bevacizumab:\n7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;\nOxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2\uff0cd1-d14, bid\uff0ceach 21 day cycle;\nOxaliplatin+5-Fluorouracil+ Levomisole\uff08FOLFOX\uff09:\nOxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole\uff08LV\uff09: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil\uff085-FU\uff09 :400mg/m2 iv,d1,then 1200mg/m2/d \u00d72d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;", 
            "intervention_name": "bevacizumab plus chemotherapy", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Capecitabine", 
                "Oxaliplatin", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bevacizumab", 
            "conversion therapy", 
            "liver metastases", 
            "colorectal cancer", 
            "objective response rate"
        ], 
        "lastchanged_date": "January 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang", 
                        "zip": "150086"
                    }, 
                    "name": "Second Affiliated Hosptial of Harbin Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "Liaoning Cancer Hospital&Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "LIAONING CANCER HOSPITAL&INSTITUTE", 
        "other_outcome": {
            "measure": "To assess the incidence of adverse events of level 3-4 \uff08Bleeding\u3001Gastrointestinal Perforation\u3001Anastomotic Fistula\u3001Hypertension\u3001Wound Healing Delay\uff09", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks after chemotherapy"
        }, 
        "overall_official": {
            "affiliation": "Professor", 
            "last_name": "Chun Song, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess the objective response rate(ORR)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks after chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763450"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Liaoning Tumor Hospital & Institute", 
            "investigator_full_name": "Chun Song", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "To assess the R0 resection rate of liver metastases", 
            "safety_issue": "No", 
            "time_frame": "8 weeks after chemotherapy\u3001every three months follow-up 1 time in R0 postoperative 1-2 years\u3001Every six months follow-up 1 time in R0 postoperative 2-5 years"
        }, 
        "source": "Liaoning Tumor Hospital & Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Liaoning Tumor Hospital & Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}